Tissue microarrays in cancer diagnosis.

Standard

Tissue microarrays in cancer diagnosis. / Simon, Ronald; Mirlacher, Martina; Sauter, Guido.

in: EXPERT REV MOL DIAGN, Jahrgang 3, Nr. 4, 4, 2003, S. 421-430.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Simon R, Mirlacher M, Sauter G. Tissue microarrays in cancer diagnosis. EXPERT REV MOL DIAGN. 2003;3(4):421-430. 4.

Bibtex

@article{b9500722fbd64e20a777c723c9dea083,
title = "Tissue microarrays in cancer diagnosis.",
abstract = "New molecular techniques such as cDNA, protein or antibody arrays allow for high-throughput identification of thousands of potentially disease-related markers on the genome, transcriptome and proteome level. Major disadvantages of such studies are the enormous costs and the need for unfixed tissues, disallowing comprehensive large-scale studies. Consequently, validation studies including large sets of clinically well-defined tissue samples are now necessary to identify those genes or proteins with true impact on the course of disease which will eventually lead to therapeutic applications. Tissue microarray technology overcomes the bottleneck of traditional tissue analysis and allows it to catch up with the rapid advances in lead discovery. Current applications and the future potential of tissue microarray technology in cancer research and diagnosis are discussed.",
author = "Ronald Simon and Martina Mirlacher and Guido Sauter",
year = "2003",
language = "Deutsch",
volume = "3",
pages = "421--430",
journal = "EXPERT REV MOL DIAGN",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - Tissue microarrays in cancer diagnosis.

AU - Simon, Ronald

AU - Mirlacher, Martina

AU - Sauter, Guido

PY - 2003

Y1 - 2003

N2 - New molecular techniques such as cDNA, protein or antibody arrays allow for high-throughput identification of thousands of potentially disease-related markers on the genome, transcriptome and proteome level. Major disadvantages of such studies are the enormous costs and the need for unfixed tissues, disallowing comprehensive large-scale studies. Consequently, validation studies including large sets of clinically well-defined tissue samples are now necessary to identify those genes or proteins with true impact on the course of disease which will eventually lead to therapeutic applications. Tissue microarray technology overcomes the bottleneck of traditional tissue analysis and allows it to catch up with the rapid advances in lead discovery. Current applications and the future potential of tissue microarray technology in cancer research and diagnosis are discussed.

AB - New molecular techniques such as cDNA, protein or antibody arrays allow for high-throughput identification of thousands of potentially disease-related markers on the genome, transcriptome and proteome level. Major disadvantages of such studies are the enormous costs and the need for unfixed tissues, disallowing comprehensive large-scale studies. Consequently, validation studies including large sets of clinically well-defined tissue samples are now necessary to identify those genes or proteins with true impact on the course of disease which will eventually lead to therapeutic applications. Tissue microarray technology overcomes the bottleneck of traditional tissue analysis and allows it to catch up with the rapid advances in lead discovery. Current applications and the future potential of tissue microarray technology in cancer research and diagnosis are discussed.

M3 - SCORING: Zeitschriftenaufsatz

VL - 3

SP - 421

EP - 430

JO - EXPERT REV MOL DIAGN

JF - EXPERT REV MOL DIAGN

SN - 1473-7159

IS - 4

M1 - 4

ER -